Codex Labs
| Company type | Private |
|---|---|
| Industry | Biotechnology, Personal care |
| Founded | 2018 |
| Founder | Barbara Paldus |
| Headquarters | Silicon Valley , United States |
| Products | Skin-gut-brain-biome therapies, topical and ingestible skincare products, dietary supplements |
Codex Labs is a biotechnology firm based in Silicon Valley, California that specializes in developing skin-gut-brain-biome therapies aimed at treating dermatological issues such as acne, eczema, rosacea, and psoriasis. Utilizing a combination of botanical ingredients and advanced biotechnology, the company creates clinically validated topical and ingestible products designed for integrative dermatologists and naturopathic practitioners.
History
Established in 2018 by Barbara Paldus, Codex Labs initially concentrated on producing skincare formulations free from phenoxyethanol, with an emphasis on maintaining the skin’s native microbiome. Early strategic initiatives included acquiring the Irish brand Bia Beauty and forming a partnership with Eurofins Dermscan in Lyon to conduct clinical evaluations. Additionally, Codex collaborated with MyMicrobiome to ensure all its products received certification for microbiome support. The company launched its inaugural skincare range in 2019 and later broadened its portfolio to include dietary supplements by 2023.
In 2019, Codex secured a patent for the PreservX system—a biotech-fermentation-based preservative designed to sustain the skin microbiome. This proprietary blend incorporates four FDA GRAS edible components: organic acids, lactobacillus ferment, coconut oil ferment, and biotech-derived propanediol. That same year, Codex released the MyMicrobiome-certified Bia collection, which targets hydration enhancement and the renewal of dry skin. The patent for BiaComplex was granted in 2020.
The Antü collection debuted in 2020 with a focus on reinforcing the skin barrier against environmental aggressors and UV radiation. Patents for AntuComplex and associated skin-protective agents were awarded in 2021.
During 2022 and 2023, the Shaant line was developed to manage sebum production, reduce redness, and mitigate acne-related inflammasome activity. Notably, Shaant’s face and body scrubs became the first over-the-counter acne treatments certified by MyMicrobiome. The ShaantComplex patent was also issued in 2022. In 2025, Codex initiated European trials for Cocoon, a functional fragrance intended to influence mood and alleviate stress. Furthermore, Codex products received approval from the National Psoriasis Foundation in 2022 as safe for individuals with sensitive psoriasis-prone skin.
In April 2025, Codex’s Bia Eczema Relief Lotion achieved both Microbiome-friendly Certification under the MyMicrobiome Standard and the Seal of Acceptance from the National Eczema Association. The following month, U.S. Patent No. 12,194,068 was granted for Shaant ClearSkin Probiotic 2.0—an oral synbiotic supplement formulated specifically for oily and acne-prone complexions.
Products
In addition to their skincare collections—BIA, ANTÜ, and SHAANT—Codex Labs offers dietary supplements aimed at supporting gut barrier health, mucosal function, inflammatory response regulation, and microbiome equilibrium. Every product undergoes clinical testing and holds certifications for being microbiome-friendly as well as vegan, cruelty-free, and environmentally sustainable.